IMM 529

Drug Profile

IMM 529

Alternative Names: IMM-529

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immuron
  • Class Anti-infectives; Polyclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Clostridium infections

Most Recent Events

  • 04 Dec 2017 Immuron has patent pending for IMM 529 in The Patent Cooperation Treaty
  • 01 Sep 2017 Phase-I/II clinical trials in Clostridium infections in Israel (PO) (NCT03065374)
  • 09 Aug 2017 Immuron receives approval for a phase I trial in Clostridium Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top